Preventive effect of Metformin against N-nitrosodiethylamine-initiated hepatocellular carcinoma in rats

Saudi Pharmaceutical Journal

Volumn 20, Issue 4, 2012, Pages 365-370

  Afzal, Muhammad ^a   Kazmi, Imran ^a   Gupta, Gaurav ^a   Rahman, Mahfoozur ^a   Kimothi, Vishwadeepak ^a   Anwar, Firoz ^a  

^a Siddhartha Institute of Pharmacy   (India)

Author keywords

Carcinogen; DENA; Hepatocellular carcinogenesis; Histology; Metformin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARCINOGEN; DIETHYLNITROSAMINE; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN; METFORMIN; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CARCINOGENESIS; CARCINOGENICITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FLUID INTAKE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; LIVER; LIVER CELL CARCINOMA; MALE; NONHUMAN; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84866771012     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsps.2012.05.012     Document Type: Article

References (37)

1. Abel S., DeKock M., vanSchalkwyk D.J., Swanevelder S., Kew M.C., Gelderblom W.C.A. Altered lipid profile, oxidative status and hepatitis B virus interactions in human hepatocellular carcinoma. Prost. Leukot. Essent. Fatty Acids 2009, 81:391-399.
2. Alwahaibi N., Mohamed J., Alhamadani A. Supplementation of selenium reduces chemical hepatocarcinogenesis in male Sprague-Dawley rats. J. Trace Elem. Med. Biol. 2010, 24(2):119-123.
3. Bartsch H., Nair J., Owen R.W. Dietary polyunsaturated fatty acids and cancers of the breast and colorectum: emerging evidence for their role as risk modifiers. Carcinogenesis 1999, 20:2209-2218.
4. Borges L.P., Borges V.C., Moro A.V., Nogueira C.W., Rocha J.B., Zeni G. Protective effect of diphenyl diselenide on acute liver damage induced by 2-nitropropane in rats. Toxicology 2005, 210:1-8.
5. Carr B.I., Lu S.N., Pancoska P. Small hepatocellular carcinoma in Chinese patients. Hepatogastroenterology 2011, 58(109):1334-1342.
6. Chen G., Xu S., Renko K., Derwahl M. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. JCEM 2012, 2012:1754.
7. Das U.N., Madhavi N., Kumar G.S., Padma M., Sangeetha P. Can tumour cell drug resistance be reversed by essential fatty acids and their metabolites?. Prost. Leukot. Essent. Fatty Acids 1998, 58:39-54.
8. Del Barco S., Vazquez-Martin A., Cufí S., Oliveras-Ferraros C., Bosch-Barrera J., Joven J., Martin-Castillo B., Menendez J.A. Metformin: multi-faceted protection against cancer. Oncotarget 2011, 2(12):896-917.
9. Donadon V., Balbi M., Mas M.D., Casarin P., Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int. 2010, 30(5):750-758.
10. Ei-Serag H., Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. NEJM 1999, 340:745-750.
11. Esfahanian, N., Shakiba, Y., Nikbin, B., Soraya, H., Maleki-Dizaji, N., Ghazi-Khansari, M., Garjani, A., 2012. Effect of Metformin on the proliferation, migration, and MMP-2 and -9 expression of human umbilical vein endothelial cells. Mol. Med. Report.
12. Gonul B., Soylemezoglu T., Erbas D. Epidermal growth factor and glucocorticoid effects on blood prostaglandin E2 level in DENA induced carcinogenesis. Prost. Leukot. Essent. Fatty Acids 1996, 55(4):257-260.
13. Goodwin P.J., Stambolic V. Obesity and insulin resistance in breast cancer-chemoprevention strategies with a focus on Metformin. Breast 2011, 20(Suppl 3):S31-S35.
14. Groupe d'Etude, et al. Traitement du Carcinome Hepatocellulaire, a comparison of lipoidol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. NEJM 1995, 332(19):1256-1261.
15. Guppy A., Jamal-Hanjani M., Pickering L. Anticancer effects of Metformin and its potential use as a therapeutic agent for breast cancer. Future Oncol. 2011, 7(6):727-736.
16. Hollstein, M.C., Wild, C.P., Bleicher, F., Chutimataewin, S., Harris, C.C., Srivatanakul, A., Montesano, R., 1993. p53 mutations and aflatoxin B1 exposure in hepatocellular carcinoma patients from Thailand. Int. J. Cancer 53, 51-55.
17. Jiang J., Nilsson-Ehle P., Xu N. Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis. 2006, 5:4.
18. Khouri, H., Collin, F., Bonnefont-Rousselot, D., Legrand, A., Jore, D., Gardès-Albert, M., 2004. Radical-induced oxidation of metformin. Eur. J. Biochem. 271, 4745-4752.
19. Klepser T.B., Kelly M.W. Metformin hydrochloride: an antihyperglycemic agent. Am. J. Health-Syst. Pharm. 1997, 54:89.
20. Kourelis T.V., Siegel R.D. Metformin and cancer: new applications for an old drug. Med. Oncol. 2011.
21. Lee A.J. Metformin in noninsulin-dependent diabetes mellitus. Pharmacotherapy 1996, 16(3):327-351.
22. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362(9399):1907-1917.
23. Lucier G.W., Tritscher A., Goldsworthy T., Foley J., Clark G., Goldstein J., Maronpot R. Ovarian hormones enhance 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated increases in cell proliferation and preneoplastic foci in a two-stage model for rat hepatocarcinogenesis. Cancer Res. 1991, 51:1391-1397.
24. Monteagudo S., Pérez-Martínez F.C., Pérez-Carrión M.D., Guerra J., Merino S., Sánchez-Verdu M.P., Ceña V. Inhibition of p42 MAPK using a nonviral vector-delivered siRNA potentiates the antitumor effect of Metformin in prostate cancer cells. Nanomedicine (London) 2011.
25. Muzio G., Marengo B., Salvo R., Semeraro A., Canuto R.A., Tessitore L. Liver cancer is induced by a subnecrogenic dose of DENA when associated with fasting/refeeding: role of glutathione-transferase and lipid peroxidation. Free Radical Biol. Med. 1999, 26(9/10):1314-1320.
26. Nkontchou G., Cosson E., Aout M., Mahmoudi A., Bourcier V., Charif I., Ganne-Carrie N., Grando-Lemaire V., Vicaut E., Trinchet J., Beaugrand M. Impact of Metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J. Clin. Endocrinol. Metab. 2011, 96:82601-82608.
27. Pancoska P., De Giorgio M., Fagiuoli S., Carr B.I. Small HCCs identified by screening. Dig. Dis. Sci. 2011, 56(10):3078-3085.
28. Parkin D.M., Bray F., Ferlay J., Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 2001, 94(2):153-156.
29. Premalatha B., Sachdanandam P. Effect of Semecarpus anacardium nut milk extract on rat serum alpha-fetoprotein level in aflatoxin B mediated hepatocellular carcinoma. Fitoterapia 1999, 70:279-283.
30. Ramanathan S., kuppusamy A., Nallasamy V.M., Perumal P. Antitumor effects and antioxidant role of Scutia myrtina in N-nitroso-diethylamine (NDEA) induced hepatocellular carcinoma in rats. Asian J. Pharm. Biol. Res. 2011, 1:2.
31. Schott S., Bierhaus A., Schuetz F., Beckhove P., Schneeweiss A., Sohn C., Domschke C. Therapeutic effects ofMetforminin breast cancer: involvement of the immune system?. Cancer Immunol. Immunother. 2011, 60(9):1221-1225.
32. Sherman M. Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment Cleveland. Clin. J. Med. 2009, 76(3):S6-S9.
33. Tapiero H., Ba G.N., Couvreur P., Tew K.D. Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. Biomed. Pharmac-other. 2002, 56:215-222.
34. Thirunavukkarasu C., Sakthisekaran D. Sodium selenite modulates tumour marker indices in N-nitrosodiethylamine initiated and phenobarbital-promoted rat liver carcinogenesis. Cell Biochem. Funct. 2003, 21:147-153.
35. Wang L.W., Li Z.S., Zou D.W., Jin Z.D., Gao J., Xu G.M. Metformin induces apoptosis of pancreatic cancer cells. World J. Gastroenterol. 2008, 14:7192-7198.
36. Xu-yinga W., Minga L., Xiao-dongb L., Ping H. Hepatoprotective and anti-hepatocarcinogenic effects of glycyrrhizin and matrine. Chemico-Biol. Interact. 2009, 181:15-19.
37. Yeo W., Mo F.K., Koh J., Chan A.T., Leung T., Hui P., Chan L., Tang A., Lee J.J., Mok T.S., Lai P.B., Johnson P.J., Zee B. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann. Oncol. 2006, 17:1083-1089.